EUVIMEDEUVIMED entdecken
Open Access

High-Grade Serous Carcinoma at Risk-Reducing Salpingo-Oophorectomy in Asymptomatic Carriers of BRCA1/2 Pathogenic Variants: Prevalence and Clinical Factors

Iris A S Stroot iD, Jan Brouwer, Joost Bart iD, Harry Hollema, Denise J Stommel-Jenner, Marise M Wagner, Helena C van Doorn iD, Joanne A de Hullu, Katja N Gaarenstroom iD, Marc Beurden, Luc R C W van Lonkhuijzen iD, Brigitte F M Slangen und 11 weitere

Journal of Clinical Oncology · 10.05.2023 · 41 (14) · 2523-2535

DOI: 10.1200/jco.22.01237 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Oncology, erschienen am 10.05.2023. Verfasst von Iris A S Stroot und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands. Hauptthemen laut MEDLINE: Ovarian Neoplasms, Carcinoma, Fallopian Tube Neoplasms. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE To investigate the prevalence of and clinical factors associated with high-grade serous carcinoma (HGSC) at risk-reducing salpingo-oophorectomy (RRSO) in asymptomatic BRCA1/2-pathogenic variant (PV) carriers. PATIENTS AND METHODS We included BRCA1/2-PV carriers who underwent RRSO between 1995 and 2018 from the Hereditary Breast and Ovarian cancer in the Netherlands study. All pathology reports were screened, and histopathology reviews were performed for RRSO specimens with epithelial abnormalities or where HGSC developed after normal RRSO. We then compared clinical characteristics, including parity and oral contraceptive pill (OCP) use, for women with and without HGSC at RRSO. RESULTS Of the 2,557 included women, 1,624 had BRCA1, 930 had BRCA2, and three had both BRCA1/2-PV. The median age at RRSO was 43.0 years (range: 25.3-73.8) for BRCA1-PV and 46.8 years (27.6-77.9) for BRCA2-PV carriers. Histopathologic review confirmed 28 of 29 HGSCs and two further HGSCs from among 20 apparently normal RRSO specimens. Thus, 24 (1.5%) BRCA1-PV and 6 (0.6%) BRCA2-PV carriers had HGSC at RRSO, with the fallopian tube identified as the primary site in 73%. The prevalence of HGSC in women who underwent RRSO at the recommended age was 0.4%. Among BRCA1/2-PV carriers, older age at RRSO increased the risk of HGSC and long-term OCP use was protective. CONCLUSION We detected HGSC in 1.5% ( BRCA1-PV) and 0.6% ( BRCA2-PV) of RRSO specimens from asymptomatic BRCA1/2-PV carriers. Consistent with the fallopian tube hypothesis, we found most lesions in the fallopian tube. Our results highlight the importance of timely RRSO with total removal and assessment of the fallopian tubes and show the protective effects of long-term OCP.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ovarian NeoplasmsCarcinomaFallopian Tube NeoplasmsFemaleHumansSalpingo-oophorectomyBRCA1 ProteinBRCA2 ProteinPrevalenceMutationGenetic Predisposition to DiseaseOvariectomy

Substanzen

BRCA1 protein, humanBRCA1 ProteinBRCA2 protein, humanBRCA2 Protein

Autor:innen und Institutionen

  • Department of Obstetrics and Gynecology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
  • Department of Epidemiology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
  • Department of Pathology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
  • Department of Epidemiology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Department of Gynecologic Oncology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, the Netherlands.
  • Department of Obstetrics and Gynecology, Radboud University Medical Center, Nijmegen, the Netherlands.

ORCID-Profile: Iris A S Stroot, Joost Bart, Helena C van Doorn, Katja N Gaarenstroom, Luc R C W van Lonkhuijzen, Ronald P Zweemer, Encarna B Gómez Garcia, Margreet G E M Ausems, Christi J van Asperen, Marjanka K Schmidt, Marijke R Wevers, Geertruida H de Bock, Marian J E Mourits

Zitieren

APA

Stroot, I. A. S., Brouwer, J., Bart, J., Hollema, H., Stommel-Jenner, D. J., Wagner, M. M., van Doorn, H. C., de Hullu, J. A., Gaarenstroom, K. N., Beurden, M., van Lonkhuijzen, L. R. C. W., Slangen, B. F. M., Zweemer, R. P., Gómez Garcia, E. B., Ausems, M. G. E. M., Boere, I. A., van Engelen, K., van Asperen, C. J., Schmidt, M. K., …, & HEBON Investigators (2023). High-Grade Serous Carcinoma at Risk-Reducing Salpingo-Oophorectomy in Asymptomatic Carriers of BRCA1/2 Pathogenic Variants: Prevalence and Clinical Factors. Journal of Clinical Oncology, 41(14), 2523-2535. https://doi.org/10.1200/jco.22.01237

Vancouver

Stroot IAS, Brouwer J, Bart J, Hollema H, Stommel-Jenner DJ, Wagner MM, et al. High-Grade Serous Carcinoma at Risk-Reducing Salpingo-Oophorectomy in Asymptomatic Carriers of BRCA1/2 Pathogenic Variants: Prevalence and Clinical Factors. Journal of Clinical Oncology. 2023;41(14):2523-2535. doi:10.1200/jco.22.01237

BibTeX
@article{Stroot2023,
  author = {Stroot, Iris A S and Brouwer, Jan and Bart, Joost and Hollema, Harry and Stommel-Jenner, Denise J and Wagner, Marise M and van Doorn, Helena C and de Hullu, Joanne A and Gaarenstroom, Katja N and Beurden, Marc and van Lonkhuijzen, Luc R C W and Slangen, Brigitte F M and Zweemer, Ronald P and Gómez Garcia, Encarna B and Ausems, Margreet G E M and Boere, Ingrid A and van Engelen, Klaartje and van Asperen, Christi J and Schmidt, Marjanka K and Wevers, Marijke R and de Bock, Geertruida H and Mourits, Marian J E and HEBON Investigators, HEBON Investigators},
  title = {High-Grade Serous Carcinoma at Risk-Reducing Salpingo-Oophorectomy in Asymptomatic Carriers of BRCA1/2 Pathogenic Variants: Prevalence and Clinical Factors},
  journal = {Journal of Clinical Oncology},
  year = {2023},
  volume = {41},
  number = {14},
  pages = {2523--2535},
  doi = {10.1200/jco.22.01237}
}
Kostenlos starten →